SiteOne Therapeutics
André Schönichen is a seasoned professional in project management and biochemistry, currently serving as Senior Director of Portfolio and Project Management at SiteOne Therapeutics, Inc. since April 2025. Prior experience includes a tenure as Director of Development Project Management at Gilead Sciences from June 2020 to December 2024, where André developed integrated timelines and facilitated team engagement. Earlier roles include Associate Director at Amgen, focusing on collaboration with diagnostic partners, and Biomarker Research Project Manager at Thermo Fisher Scientific, directing biomarker discovery projects. André began a career in research as a Postdoctoral Researcher at the University of California, San Francisco, contributing to several publications and securing research funding. André holds a Dr. rer. nat. in Biochemistry from TU Dortmund University and a Diplom in Biochemistry from Leibniz Universität Hannover.
This person is not in any teams
This person is not in any offices
SiteOne Therapeutics
SiteOne Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of hypersensitivity disorders such as chronic cough, itch, and pain.